Lovastatin Treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Resistance to anticancer drugs is a problem in the treatment of pancreatic ductal carcinoma (PDAC) and overcoming it is an important issue. Recently, it has been reported that statins induce apoptosis in cancer cells but the mechanism has not been completely elucidated. We investigated the antitumor mechanisms of statins against PDAC and their impact on resistance to gemcitabine (GEM). Lovastatin (LOVA) increased mitochondrial oxidative stress in PDAC cells, leading to apoptosis. LOVA reduced lipid rafts in the plasma membrane and mitochondria, suppressed the activation of epithelial growth factor receptor (EGFR) and AKT in plasma membrane rafts, and reduced B-cell lymphoma 2 (BCL2)-Bcl-2-associated X protein (BAX) binding and the translocation of F1F0 ATPase in mitochondrial rafts. In the three GEM-resistant cell lines derived from MIA and PANC1, the lipid rafts in the cell membrane and the mitochondria were increased to activate EGFR and AKT and to increase BCL2-BAX binding, which suppressed apoptosis. LOVA abrogated these anti-apoptotic effects by reducing the rafts in the resistant cells. By treating the resistant cells with LOVA, GEM sensitivity improved to the level of the parental cells. Therefore, cholesterol rafts contribute to drug resistance in PDAC. Further clinical research is warranted on overcoming anticancer drug resistance by statin-mediated intracellular cholesterol regulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gyoten et al. observed, in three gemcitabine-resistant PDAC cell lines, an increased activity of the epidermal growth factor receptor (EGFR)-Akt axis, which in turn increased the binding of B-cell lymphoma 2 (BCL2)-Bcl-2-associated X protein (BAX), thus suppressing apoptosis.”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Gyoten et al., 2023
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A convergent mechanism identified across multiple studies is the disruption of plasma membrane lipid rafts by statins through intracellular cholesterol depletion (Duranti et al., 2025; Gyoten et al., 2023).”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Gyoten et al., 2023
The cited source says what the claim attributes to it.
In the citing paper
“This effect was countered by the lovastatin treatment, by disrupting the lipid rafts in the cell and mitochondria membranes, and by increasing mitochondrial oxidative stress (Gyoten et al., 2023).”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Gyoten et al., 2023
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Park, W., Chawla, A., & O’Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 1,882
Hyperlipidemia as a Risk Factor for Cardiovascular Disease
Nelson, R. H. (2013) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2012.11.003 · Cited by 1,093
Bax, Bak and beyond — mitochondrial performance in apoptosis
Peña‐Blanco, A., & García‐Sáez, A. J. (2018) · The FEBS Journal · doi:10.1111/febs.14186 · Cited by 930
Statins: mechanism of action and effects
Stancu, C., & Sima, A. (2001) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2001.tb00172.x · Cited by 911 · cited 1×
“Statins inhibit the rate-limiting reaction of cholesterol synthesis in which 3-hydroxy-3-methylglutaryl coenzyme A (HMGC) is converted to mevalonate by HMGC reductase [14].”
BackgroundChemoresistance in Pancreatic Cancer
Zeng, S., Pöttler, M., Lan, B., Grützmann, R., Pilarsky, C., & Yang, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184504 · Cited by 611
Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance
Sherman, M. H., & Beatty, G. L. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031621-024600 · Cited by 467
Oxidative Stress, Redox Signaling, and Autophagy: Cell Death Versus Survival
Navarro-Yepes, J., Burns, M., Anandhan, A., Khalimonchuk, O., del Razo, L. M., Quintanilla-Vega, B., Pappa, A., Panayiotidis, M. I., & Franco, R. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.5837 · Cited by 449
Statins: a repurposed drug to fight cancer
Jiang, W., Hu, J.-W., He, X.-R., Jin, W.-L., & He, X.-Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02041-2 · Cited by 417
Gemcitabine resistance in pancreatic ductal adenocarcinoma
Binenbaum, Y., Na’ara, S., & Gil, Z. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.002 · Cited by 414
Targeting hypoxic tumor microenvironment in pancreatic cancer
Tao, J., Yang, G., Zhou, W., Qiu, J., Chen, G., Luo, W., Zhao, F., You, L., Zheng, L., Zhang, T., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01030-w · Cited by 412
Zhou, P., Li, B., Liu, F., Zhang, M., Wang, Q., Liu, Y., Yao, Y., & Li, D. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0624-9 · Cited by 337
Kuniyasu, H., Oue, N., Wakikawa, A., Shigeishi, H., Matsutani, N., Kuraoka, K., Ito, R., Yokozaki, H., & Yasui, W. (2002) · The Journal of Pathology · doi:10.1002/path.1031 · Cited by 325
Self-citationCholesterol Depletion Using Methyl-β-cyclodextrin
Mahammad, S., & Parmryd, I. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-1752-5_8 · Cited by 276
Lipid raft: A floating island of death or survival
George, K. S., & Wu, S. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.01.007 · Cited by 205
Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis
Okusaka, T., Nakamura, M., Yoshida, M., Kitano, M., Uesaka, K., Ito, Y., Furuse, J., Hanada, K., & Okazaki, K. (2020) · Pancreas · doi:10.1097/mpa.0000000000001513 · Cited by 165
Vallianou, N., Kostantinou, A., Kougias, M., & Kazazis, C. (2014) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520613666131129105035 · Cited by 136
Feo, F., Canuto, R. A., Garcea, R., & Gabriel, L. (1975) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(75)90063-2 · Cited by 97
Minireview: Translocator Protein (TSPO) and Steroidogenesis: A Reappraisal
Selvaraj, V., Stocco, D. M., & Tu, L. N. (2015) · Molecular Endocrinology · doi:10.1210/me.2015-1033 · Cited by 81
Lee, E. J., Yun, U.-J., Koo, K. H., Sung, J. Y., Shim, J., Ye, S.-K., Hong, K., & Kim, Y.-N. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.10.006 · Cited by 69
Jian-Yu, E., Graber, J. M., Lu, S.-E., Lin, Y., Lu-Yao, G., & Tan, X.-L. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170412145232 · Cited by 67
Role of mitochondrial raft-like microdomains in the regulation of cell apoptosis
Garofalo, T., Manganelli, V., Grasso, M., Mattei, V., Ferri, A., Misasi, R., & Sorice, M. (2015) · APOPTOSIS · doi:10.1007/s10495-015-1100-x · Cited by 66
Müller, C., Bockhorn, A. G., Klusmeier, S., Kiehl, M. G., Röder, C., Kalthoff, H., & Koch, O. M. (1998) · International Journal of Oncology · doi:10.3892/ijo.12.3.717 · Cited by 64
Mitochondrial F-ATP synthase as the permeability transition pore
Gerle, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105081 · Cited by 60
Statin Use and Its Impact on Survival in Pancreatic Cancer Patients
Lee, H. S., Lee, S. H., Lee, H. J., Chung, M. J., Park, J. Y., Park, S. W., Song, S. Y., & Bang, S. (2016) · Medicine · doi:10.1097/md.0000000000003607 · Cited by 58
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis
Tummala, R., Gupta, M., Devanabanda, A. R., Bandyopadhyay, D., Aronow, W. S., Ray, K. K., Mamas, M. A., & Ghosh, R. K. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2059559 · Cited by 56
Role of oxidative stress-mediated cell death and signaling pathways in experimental fluorosis
Babu, S., Manoharan, S., Ottappilakkil, H., & Perumal, E. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110106 · Cited by 51
Yu, S., Wang, L., Che, D., Zhang, M., Li, M., Naito, M., Xin, W., & Zhou, L. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02261-0 · Cited by 48
Mannino, G., Iovino, P., Lauria, A., Genova, T., Asteggiano, A., Notarbartolo, M., Porcu, A., Serio, G., Chinigò, G., Occhipinti, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052664 · Cited by 40
Cholesterol-Lowering Drugs on Akt Signaling for Prevention of Tumorigenesis
Kumar, N., & Mandal, C. C. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.724149 · Cited by 32
Cheng, B., Hsu, D. K., & Kimura, T. (1985) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(85)90179-0 · Cited by 29
Fujiwara‐Tani, R., Fujii, K., Mori, S., Kishi, S., Sasaki, T., Ohmori, H., Nakashima, C., Kawahara, I., Nishiguchi, Y., Mori, T., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113840 · Cited by 29
Self-citationFujiwara‐Tani, R., Sasaki, T., Takagi, T., Mori, S., Kishi, S., Nishiguchi, Y., Ohmori, H., Fujii, K., & Kuniyasu, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147824 · Cited by 29
Self-citationPro‑metastatic signaling of the trans fatty acid elaidic acid is associated with lipid rafts
Kishi, S., Fujiwara‐Tani, R., Luo, Y., Kawahara, I., Goto, K., Fujii, K., Ohmori, H., Nakashima, C., Sasaki, T., & Kuniyasu, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.7817 · Cited by 22
Self-citationMollinedo, F., & Gajate, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050763 · Cited by 22
Gajate, C., & Mollinedo, F. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0814-2_9 · Cited by 22
Takagi, T., Fujiwara‐Tani, R., Mori, S., Kishi, S., Nishiguchi, Y., Sasaki, T., Ogata, R., Ikemoto, A., Sasaki, R., Ohmori, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087506 · Cited by 21
Self-citationSaito, K., Sato, Y., Nakatani, E., Kaneda, H., Yamamoto, S., Miyachi, Y., & Itoh, H. (2021) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-21-0123 · Cited by 19
Chinopoulos, C., & Szabadkai, G. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00025 · Cited by 13
[Extended worldwide experience. HMG-CoA reductase inhibitors: lovastatin and simvastatin].
Mantell, G. (1992) · PubMed · Cited by 3
Cited by
Oyón, D., López-Pascual, A., Castelló-Uribe, B., Uriarte, I., Orsi, G., Llorente, S., Elurbide, J., Adán-Villaescusa, E., Valbuena-Goiricelaya, E., Irigaray-Miramon, A., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03268-5 · Cited by 26
Karthikeyan, S., Somasundaram, P., Karimi, I., Lagunas‐Rangel, F. A., Alsehli, A. M., Fredriksson, R., Jonsson, J., & Schiöth, H. B. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107912 · Cited by 26
Caveolae: Metabolic Platforms at the Crossroads of Health and Disease
Stea, D. M., & D’Alessio, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072918 · Cited by 21
Zabielska, J., Stelmańska, E., Szrok-Jurga, S., Kobiela, J., & Czumaj, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031186 · Cited by 14
Li, W., Xu, J., Long, Y., Zhang, H., Rong, X., & Su, Z. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101945 · Cited by 10
Metadata
- Authors
- Gyoten, M., Luo, Y., Fujiwara-Tani, R., Mori, S., Ogata, R., Kishi, S., & Kuniyasu, H.
- Affiliations
- Nara Medical University (JP)
- Nantong University (CN)
- Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan
- Nozaki Tokushukai Hospital (JP)
- Corresponding author
- Kuniyasu, Hiroki
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-11-27
- Volume
- 24
- Issue
- 23
- Pages
- 16814
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10706654
- OpenAlex
- W4389048098
- Cited by
- 28
- References
- 40
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 3
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- MEXT KAKENHI (19K16564, 20K21659, 23K16621, 23K19900)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Caveolin-1 and cellular processes
- Keywords
- lovastatin, statins, pancreatic ductal carcinoma, apoptosis, lipid rafts, gemcitabine resistance, mitochondrial oxidative stress, EGFR, Akt, chemoresistance
- MeSH terms
- Gemcitabine, Antineoplastic Agents, Cell Membrane, Cholesterol, Humans, Lovastatin, Mitochondria, Pancreatic Neoplasms, Apoptosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Carcinoma, Pancreatic Ductal, Membrane Microdomains, Cell Line, Tumor, bcl-2-Associated X Protein, Proto-Oncogene Proteins c-akt, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.